嵌合抗原受体
单克隆抗体
免疫疗法
抗原
抗体
癌症研究
癌症免疫疗法
免疫学
肝细胞癌
受体
效应器
医学
生物
免疫系统
内科学
作者
Sayed Shahabuddin Hoseini,Nai‐Kong V. Cheung
标识
DOI:10.1016/j.canlet.2017.04.013
摘要
Hepatocellular carcinoma (HCC) is one of the most lethal cancers worldwide with an overall survival rate of less than 15% in developed countries. Despite attempts at new therapeutic strategies, the majority of patients succumb to this cancer. Buttressed by the highly successful clinical impact in melanoma, immunotherapy is gaining momentum as the next treatment modality for many human cancers. Chimeric antigen receptors (CAR) contain the antigen binding moieties of a monoclonal antibody and the co-stimulatory and signaling domains associated with effector receptor signaling. Bispecific antibodies (BsAb) combine the binding specificities of two different monoclonal antibodies, one activating a receptor on a killer effector cell, while the other engaging a tumor-associated antigen to initiate tumor cytotoxicity. In this review, we survey the HCC targets for which CARs and bispecific antibodies have been generated. The pros and cons of these targets for T-cell and Natural Killer cell based immunotherapy will be discussed.
科研通智能强力驱动
Strongly Powered by AbleSci AI